Clinical Trials on Richter's Transformation

Total 245 results

University of Los Andes, Columbia
Wellcome Trust; Drexel University; Fundación Santa Fe de Bogota

Active, not recruiting

Urban Transformations and Health: The Case of TransMiCable in Bogotá (TRUST)

Quality of Life | Physical Activity | Respiratory Disease | Social Capital | Transportation | Homicide

Colombia
University of Alberta

Completed

Lixiana Acute Stroke Evaluation Registry (LASER)

Ischemic Stroke | Atrial Fibrillation | Hemorrhagic Transformation Stroke

Canada
Prelude Therapeutics
BeiGene

Recruiting

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies

T-cell Lymphoma | Mantle Cell Lymphoma (MCL) | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Syndrome | Aggressive B-Cell Non-Hodgkin's Lymphoma | Aggressive B-Cell NHL

United States, Canada, Korea, Republic of, Australia, France, Poland, Italy, Germany, Switzerland, United Kingdom
Instituto de Investigación Hospital Universitario...
Daiichi Sankyo, Inc.; Hospital Universitario La Paz; Fundación Freno al ICTUS

Recruiting

Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke (KOALA-IS)

Cardioembolic Stroke | Stroke Recurrence | Anticoagulant Therapy | Haemorrhagic Transformation Stroke

Spain, France
National Taiwan University Hospital

Completed

The Role of Aromatic Hydrocarbon Receptor in the Tumorigenesis of Neuroblastoma and Its Relationship With MYCN Expression

Neuroblastoma
Beijing Tiantan Hospital

Not yet recruiting

Cerebral Autoregulation Guiding Blood Pressure Management After Revascularization (RESCUE-CA)

Ischemic Stroke | Blood Pressure | Cerebral Autoregulation | Revascularization | Cerebrovascular Insufficiency | Individuation | Hemorrhagic Transformation Due to Acute Stroke
Novartis

Completed

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

Leukemia

United States
Novartis Pharmaceuticals

Approved for marketing

Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Mexico
Novartis Pharmaceuticals

Completed

A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Colombia, Venezuela
University of Rochester

Completed

Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Leukemia

United States
Novartis Pharmaceuticals

Completed

Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (MACS0439)

Chronic Myeloid Leukemia

Brazil
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Leukemia, Myeloid, Chronic

United States, Germany
Joseph Jurcic
Bristol-Myers Squibb

Terminated

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Myeloproliferative Neoplasm

United States
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Chronic Myeloid Leukemia | Blast Crisis

Netherlands, United States, Italy, Austria, Canada, France, Germany, Singapore, Taiwan, United Kingdom, Australia, Korea, Republic of, Philippines, Sweden, Finland, Israel, Belgium, Denmark, Norway, Switzerland
Fundació Institut de Recerca de l'Hospital de la...
Hospital Clinic of Barcelona; Germans Trias i Pujol Hospital; Hospital Arnau... and other collaborators

Recruiting

Registry of Patients With Remote Posterior cErebral Hemorrhage Following Reperfusion Treatment in Ischemic Stroke (HEROES-CAT)

Ischemic Stroke | Intracranial Hemorrhages | Hemorrhagic Transformation Stroke

Spain
King Faisal Specialist Hospital & Research Center

Completed

An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Leukemia, Myeloid, Chronic
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

Leukemia

United States, Australia, Canada
University of Bologna

Completed

Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase (CML003)

Chronic Myeloid Leukemia

Italy
University of Jena

Recruiting

European CML Blast Crisis Register (BlastCrisis)

Chronic Myeloid Leukemia in Myeloid Blast Crisis

Germany, Czechia, Russian Federation, Ukraine
Samus Therapeutics, Inc.

Withdrawn

A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN (AP-MPN)

Accelerated Phase MPN | Blast Phase MPN
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Leukemia

United States
Astex Pharmaceuticals, Inc.
Eisai Inc.

Completed

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Chronic Myelogenous Leukemia

United States, Canada
Acerta Pharma BV
Merck Sharp & Dohme LLC

Active, not recruiting

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)

Multiple Myeloma | Hodgkin Lymphoma | Waldenström Macroglobulinemia | Burkitt Lymphoma | Small Lymphocytic Lymphoma (SLL) | Hairy Cell Leukemia | CLL | Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Richter's Syndrome | Indolent Non Hodgkin Lymphoma | Marginal Zone Lymphomas | Mediastinal Large B Cell...

United States
M.D. Anderson Cancer Center

Recruiting

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
Zaibo Jiang

Unknown

TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV

Liver Cirrhosis | Portal Vein Thrombosis | Bleeding Esophageal Varices | Portal Vein, Cavernous Transformation of

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
Novartis Pharmaceuticals

Completed

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

Chronic Myelogenous Leukemia

Poland
Novartis Pharmaceuticals

No longer available

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Chronic Myelogenous Leukemia

Canada
University of Cincinnati
Novartis

Withdrawn

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myeloid Leukemia, Blast Crisis

United States
Institut de cancérologie Strasbourg Europe

Not yet recruiting

Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B (SCARA-B)

Breast Neoplasms

France
Versailles Hospital

Recruiting

PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS (PONAZA)

CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE | CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS

France
Istituto di Neuroscienze Consiglio Nazionale delle...
Careggi Hospital; University of Florence

Enrolling by invitation

Acute Ischaemic STROKE: From LAboratory to the Patient's BED (STROKELABED)

Reperfusion Injury | Acute Ischemic Stroke | Cerebral Edema | Hemorrhagic Transformation Due to Acute Stroke | Animal Model
Mansoura University

Completed

Enteropathogenic Escherichia Coli (EPEC): Does it Have a Role in Colorectal Tumourigenesis? (EPEC)

Colorectal Carcinoma | Enteropathogenic Escherichia Coli .

Egypt
National Cancer Institute (NCI)

Completed

6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

Myelodysplastic Syndromes | Leukemia

United States
TG Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center

Completed

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

Chronic Lymphocytic Leukemia | Richter Syndrome

United States
Vion Pharmaceuticals

Completed

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

Lymphoma | Leukemia

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)

Richter Syndrome | Mediastinal Large B-cell Lymphoma
John Mascarenhas
National Cancer Institute (NCI); National Institutes of Health (NIH); Celgene... and other collaborators

Completed

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

IDH2 Mutation | Accelerated/Blast-phase Myeloproliferative Neoplasm | Chronic-phase Myelofibrosis

United States, Canada
Novartis Pharmaceuticals

Completed

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

Philadelphia Chromosome Positive CML

United States, Germany, Italy, France
Ulsan University Hospital
The Korean Society of Hematology CML working party

Unknown

Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML (NICE-BORA)

Untreated Adult Acute Myeloid Leukemia | Chronic Myeloid Leukemia in Myeloid Blast Crisis

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)

Myelodysplastic Syndromes | Leukemia | Blast Crisis | Leukemia, Lymphocytic | Leukemia, Myeloid, Chronic
Weill Medical College of Cornell University
Genentech, Inc.

Recruiting

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Chronic Lymphocytic Leukemia | Richter Syndrome

United States
Ariad Pharmaceuticals
United BioSource, LLC

Terminated

An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® (OMNI)

Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Terminated

Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Completed

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands
Dana-Farber Cancer Institute
Secura Bio, Inc.

Recruiting

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Chronic Lymphocytic Leukemia | Richter Syndrome

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Previously Treated Myelodysplastic Syndromes | Recurrent Adult Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Blastic Phase Chronic Myelogenous Leukemia and other conditions

United States

Clinical Trials on Richter's Transformation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations